APO Research
Talk to an analyst

APO RESEARCH · REPORT

PECAM-1 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PECAM-1 Antibody Market Outlook and Growth Opportunities 2026

31 December 2025214 pages

Choose your research edition.

Industry ResearchPECAM-1 Antibody Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal PECAM-1 Antibody Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal PECAM-1 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PECAM-1 Antibody Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal PECAM-1 Antibody Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global PECAM-1 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PECAM-1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PECAM-1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PECAM-1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PECAM-1 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PECAM-1 Antibody market include Thermo Fisher, YO Proteins, US Biological, SICGEN, Santa Cruz Biotechnology, Rockland Immunochemicals, R&D Systems, Proteintech Group and OriGene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PECAM-1 Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PECAM-1 Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PECAM-1 Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PECAM-1 Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

PECAM-1 Antibody Segment by Company

Thermo Fisher

YO Proteins

US Biological

SICGEN

Santa Cruz Biotechnology

Rockland Immunochemicals

R&D Systems

Proteintech Group

OriGene

Novus Biologicals

Miltenyi Biotec

MilliporeSigma

LifeSpan Biosciences

Enzo Life Sciences

Dianova

Creative Biomart

Boster

Bon Opus Biosciences

Bio-Rad

BioLegend

Abnova

Abeomics

Abcam

PECAM-1 Antibody Segment by Type

Mouse

Rabbit

Others

PECAM-1 Antibody Segment by Application

Laboratory

Hospital

Others

PECAM-1 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global PECAM-1 Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PECAM-1 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PECAM-1 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze PECAM-1 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PECAM-1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PECAM-1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PECAM-1 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PECAM-1 Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PECAM-1 Antibody industry.

Chapter 3: Detailed analysis of PECAM-1 Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PECAM-1 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PECAM-1 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PECAM-1 Antibody Industry Trends Table 2. PECAM-1 Antibody Industry Drivers Table 3. PECAM-1 Antibody Industry Opportunities and Challenges Table 4. PECAM-1 Antibody Industry Restraints Table 5. Global PECAM-1 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PECAM-1 Antibody Revenue Share by Company (2021-2026) Table 7. Global PECAM-1 Antibody Sales Volume by Company (Kg) & (2021-2026) Table 8. Global PECAM-1 Antibody Sales Volume Share by Company (2021-2026) Table 9. Global PECAM-1 Antibody Average Price (US$/g) of Company (2021-2026) Table 10. Global PECAM-1 Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global PECAM-1 Antibody Key Company Manufacturing Base & Headquarters Table 12. Global PECAM-1 Antibody Company, Product Type & Application Table 13. Global PECAM-1 Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PECAM-1 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Mouse Table 18. Significant Companies of Rabbit Table 19. Significant Companies of Others Table 20. Global PECAM-1 Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 21. Global PECAM-1 Antibody Sales Volume by Type (2021-2026) & (Kg) Table 22. Global PECAM-1 Antibody Sales Volume by Type (2027-2032) & (Kg) Table 23. Global PECAM-1 Antibody Sales Volume Share by Type (2021-2026) Table 24. Global PECAM-1 Antibody Sales Volume Share by Type (2027-2032) Table 25. Global PECAM-1 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PECAM-1 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global PECAM-1 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global PECAM-1 Antibody Sales Value Share by Type (2021-2026) Table 29. Global PECAM-1 Antibody Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Laboratory Table 31. Significant Companies of Hospital Table 32. Significant Companies of Others Table 33. Global PECAM-1 Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 34. Global PECAM-1 Antibody Sales Volume by Application (2021-2026) & (Kg) Table 35. Global PECAM-1 Antibody Sales Volume by Application (2027-2032) & (Kg) Table 36. Global PECAM-1 Antibody Sales Volume Share by Application (2021-2026) Table 37. Global PECAM-1 Antibody Sales Volume Share by Application (2027-2032) Table 38. Global PECAM-1 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global PECAM-1 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global PECAM-1 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global PECAM-1 Antibody Sales Value Share by Application (2021-2026) Table 42. Global PECAM-1 Antibody Sales Value Share by Application (2027-2032) Table 43. Global PECAM-1 Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 44. Global PECAM-1 Antibody Sales by Region (2021-2026) & (Kg) Table 45. Global PECAM-1 Antibody Sales Market Share by Region (2021-2026) Table 46. Global PECAM-1 Antibody Sales by Region (2027-2032) & (Kg) Table 47. Global PECAM-1 Antibody Sales Market Share by Region (2027-2032) Table 48. Global PECAM-1 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global PECAM-1 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global PECAM-1 Antibody Sales Value Share by Region (2021-2026) Table 51. Global PECAM-1 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global PECAM-1 Antibody Sales Value Share by Region (2027-2032) Table 53. Global PECAM-1 Antibody Market Average Price (US$/g) by Region (2021-2026) Table 54. Global PECAM-1 Antibody Market Average Price (US$/g) by Region (2027-2032) Table 55. Global PECAM-1 Antibody Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 56. Global PECAM-1 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global PECAM-1 Antibody Sales by Country (2021-2026) & (Kg) Table 58. Global PECAM-1 Antibody Sales Market Share by Country (2021-2026) Table 59. Global PECAM-1 Antibody Sales by Country (2027-2032) & (Kg) Table 60. Global PECAM-1 Antibody Sales Market Share by Country (2027-2032) Table 61. Global PECAM-1 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global PECAM-1 Antibody Sales Value Market Share by Country (2021-2026) Table 63. Global PECAM-1 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global PECAM-1 Antibody Sales Value Market Share by Country (2027-2032) Table 65. Thermo Fisher Company Information Table 66. Thermo Fisher Business Overview Table 67. Thermo Fisher PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 68. Thermo Fisher PECAM-1 Antibody Product Portfolio Table 69. Thermo Fisher Recent Development Table 70. YO Proteins Company Information Table 71. YO Proteins Business Overview Table 72. YO Proteins PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 73. YO Proteins PECAM-1 Antibody Product Portfolio Table 74. YO Proteins Recent Development Table 75. US Biological Company Information Table 76. US Biological Business Overview Table 77. US Biological PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 78. US Biological PECAM-1 Antibody Product Portfolio Table 79. US Biological Recent Development Table 80. SICGEN Company Information Table 81. SICGEN Business Overview Table 82. SICGEN PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 83. SICGEN PECAM-1 Antibody Product Portfolio Table 84. SICGEN Recent Development Table 85. Santa Cruz Biotechnology Company Information Table 86. Santa Cruz Biotechnology Business Overview Table 87. Santa Cruz Biotechnology PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 88. Santa Cruz Biotechnology PECAM-1 Antibody Product Portfolio Table 89. Santa Cruz Biotechnology Recent Development Table 90. Rockland Immunochemicals Company Information Table 91. Rockland Immunochemicals Business Overview Table 92. Rockland Immunochemicals PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 93. Rockland Immunochemicals PECAM-1 Antibody Product Portfolio Table 94. Rockland Immunochemicals Recent Development Table 95. R&D Systems Company Information Table 96. R&D Systems Business Overview Table 97. R&D Systems PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 98. R&D Systems PECAM-1 Antibody Product Portfolio Table 99. R&D Systems Recent Development Table 100. Proteintech Group Company Information Table 101. Proteintech Group Business Overview Table 102. Proteintech Group PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 103. Proteintech Group PECAM-1 Antibody Product Portfolio Table 104. Proteintech Group Recent Development Table 105. OriGene Company Information Table 106. OriGene Business Overview Table 107. OriGene PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 108. OriGene PECAM-1 Antibody Product Portfolio Table 109. OriGene Recent Development Table 110. Novus Biologicals Company Information Table 111. Novus Biologicals Business Overview Table 112. Novus Biologicals PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 113. Novus Biologicals PECAM-1 Antibody Product Portfolio Table 114. Novus Biologicals Recent Development Table 115. Miltenyi Biotec Company Information Table 116. Miltenyi Biotec Business Overview Table 117. Miltenyi Biotec PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 118. Miltenyi Biotec PECAM-1 Antibody Product Portfolio Table 119. Miltenyi Biotec Recent Development Table 120. MilliporeSigma Company Information Table 121. MilliporeSigma Business Overview Table 122. MilliporeSigma PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 123. MilliporeSigma PECAM-1 Antibody Product Portfolio Table 124. MilliporeSigma Recent Development Table 125. LifeSpan Biosciences Company Information Table 126. LifeSpan Biosciences Business Overview Table 127. LifeSpan Biosciences PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 128. LifeSpan Biosciences PECAM-1 Antibody Product Portfolio Table 129. LifeSpan Biosciences Recent Development Table 130. Enzo Life Sciences Company Information Table 131. Enzo Life Sciences Business Overview Table 132. Enzo Life Sciences PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 133. Enzo Life Sciences PECAM-1 Antibody Product Portfolio Table 134. Enzo Life Sciences Recent Development Table 135. Dianova Company Information Table 136. Dianova Business Overview Table 137. Dianova PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 138. Dianova PECAM-1 Antibody Product Portfolio Table 139. Dianova Recent Development Table 140. Creative Biomart Company Information Table 141. Creative Biomart Business Overview Table 142. Creative Biomart PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 143. Creative Biomart PECAM-1 Antibody Product Portfolio Table 144. Creative Biomart Recent Development Table 145. Boster Company Information Table 146. Boster Business Overview Table 147. Boster PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 148. Boster PECAM-1 Antibody Product Portfolio Table 149. Boster Recent Development Table 150. Bon Opus Biosciences Company Information Table 151. Bon Opus Biosciences Business Overview Table 152. Bon Opus Biosciences PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 153. Bon Opus Biosciences PECAM-1 Antibody Product Portfolio Table 154. Bon Opus Biosciences Recent Development Table 155. Bio-Rad Company Information Table 156. Bio-Rad Business Overview Table 157. Bio-Rad PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 158. Bio-Rad PECAM-1 Antibody Product Portfolio Table 159. Bio-Rad Recent Development Table 160. BioLegend Company Information Table 161. BioLegend Business Overview Table 162. BioLegend PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 163. BioLegend PECAM-1 Antibody Product Portfolio Table 164. BioLegend Recent Development Table 165. Abnova Company Information Table 166. Abnova Business Overview Table 167. Abnova PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 168. Abnova PECAM-1 Antibody Product Portfolio Table 169. Abnova Recent Development Table 170. Abeomics Company Information Table 171. Abeomics Business Overview Table 172. Abeomics PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 173. Abeomics PECAM-1 Antibody Product Portfolio Table 174. Abeomics Recent Development Table 175. Abcam Company Information Table 176. Abcam Business Overview Table 177. Abcam PECAM-1 Antibody Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 178. Abcam PECAM-1 Antibody Product Portfolio Table 179. Abcam Recent Development Table 180. Key Raw Materials Table 181. Raw Materials Key Suppliers Table 182. PECAM-1 Antibody Distributors List Table 183. PECAM-1 Antibody Customers List Table 184. Research Programs/Design for This Report Table 185. Authors List of This Report Table 186. Secondary Sources Table 187. Primary Sources List of Figures Figure 1. PECAM-1 Antibody Product Image Figure 2. Global PECAM-1 Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global PECAM-1 Antibody Sales (2021-2032) & (Kg) Figure 5. Global PECAM-1 Antibody Sales Average Price (US$/g) & (2021-2032) Figure 6. Global PECAM-1 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Mouse Image Figure 10. Rabbit Image Figure 11. Others Image Figure 12. Global PECAM-1 Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 13. Global PECAM-1 Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global PECAM-1 Antibody Sales Volume Share by Type (2021-2032) Figure 15. Global PECAM-1 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PECAM-1 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PECAM-1 Antibody Sales Value Share by Type (2021-2032) Figure 18. Laboratory Image Figure 19. Hospital Image Figure 20. Others Image Figure 21. Global PECAM-1 Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 22. Global PECAM-1 Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global PECAM-1 Antibody Sales Volume Share by Application (2021-2032) Figure 24. Global PECAM-1 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global PECAM-1 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global PECAM-1 Antibody Sales Value Share by Application (2021-2032) Figure 27. Global PECAM-1 Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 28. Global PECAM-1 Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global PECAM-1 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global PECAM-1 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. North America PECAM-1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 34. Europe PECAM-1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific PECAM-1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 38. South America PECAM-1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa PECAM-1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa PECAM-1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt PECAM-1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. PECAM-1 Antibody Value Chain Figure 126. Manufacturing Cost Structure Figure 127. PECAM-1 Antibody Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Mouse
  • Rabbit
  • Others
Applications
  • Laboratory
  • Hospital
  • Others
Companies covered
  • Thermo Fisher
  • YO Proteins
  • US Biological
  • SICGEN
  • Santa Cruz Biotechnology
  • Rockland Immunochemicals
  • R&D Systems
  • Proteintech Group
  • OriGene
  • Novus Biologicals
  • Miltenyi Biotec
  • MilliporeSigma
  • LifeSpan Biosciences
  • Enzo Life Sciences
  • Dianova
  • Creative Biomart
  • Boster
  • Bon Opus Biosciences
  • Bio-Rad
  • BioLegend
  • Abnova
  • Abeomics
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PECAM-1 Antibody Sales Value (2021-2032)
  4. 1.2.2 Global PECAM-1 Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global PECAM-1 Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PECAM-1 Antibody Market Dynamics
  1. 2.1 PECAM-1 Antibody Industry Trends
  2. 2.2 PECAM-1 Antibody Industry Drivers
  3. 2.3 PECAM-1 Antibody Industry Opportunities and Challenges
  4. 2.4 PECAM-1 Antibody Industry Restraints
3 PECAM-1 Antibody Market by Company
  1. 3.1 Global PECAM-1 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global PECAM-1 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global PECAM-1 Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global PECAM-1 Antibody Average Price by Company (2021-2026)
  5. 3.5 Global PECAM-1 Antibody Company Ranking (2024-2026)
  6. 3.6 Global PECAM-1 Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global PECAM-1 Antibody Company Product Type and Application
  8. 3.8 Global PECAM-1 Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PECAM-1 Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PECAM-1 Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PECAM-1 Antibody Market by Type
  1. 4.1 PECAM-1 Antibody Type Introduction
  2. 4.1.1 Mouse
  3. 4.1.2 Rabbit
  4. 4.1.3 Others
  5. 4.2 Global PECAM-1 Antibody Sales Volume by Type
  6. 4.2.1 Global PECAM-1 Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PECAM-1 Antibody Sales Volume by Type (2021-2032)
  8. 4.2.3 Global PECAM-1 Antibody Sales Volume Share by Type (2021-2032)
  9. 4.3 Global PECAM-1 Antibody Sales Value by Type
  10. 4.3.1 Global PECAM-1 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PECAM-1 Antibody Sales Value by Type (2021-2032)
  12. 4.3.3 Global PECAM-1 Antibody Sales Value Share by Type (2021-2032)
5 PECAM-1 Antibody Market by Application
  1. 5.1 PECAM-1 Antibody Application Introduction
  2. 5.1.1 Laboratory
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global PECAM-1 Antibody Sales Volume by Application
  6. 5.2.1 Global PECAM-1 Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PECAM-1 Antibody Sales Volume by Application (2021-2032)
  8. 5.2.3 Global PECAM-1 Antibody Sales Volume Share by Application (2021-2032)
  9. 5.3 Global PECAM-1 Antibody Sales Value by Application
  10. 5.3.1 Global PECAM-1 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PECAM-1 Antibody Sales Value by Application (2021-2032)
  12. 5.3.3 Global PECAM-1 Antibody Sales Value Share by Application (2021-2032)
6 PECAM-1 Antibody Regional Sales and Value Analysis
  1. 6.1 Global PECAM-1 Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PECAM-1 Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global PECAM-1 Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global PECAM-1 Antibody Sales by Region (2027-2032)
  5. 6.3 Global PECAM-1 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PECAM-1 Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global PECAM-1 Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global PECAM-1 Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global PECAM-1 Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PECAM-1 Antibody Sales Value (2021-2032)
  12. 6.6.2 North America PECAM-1 Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PECAM-1 Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe PECAM-1 Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PECAM-1 Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PECAM-1 Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PECAM-1 Antibody Sales Value (2021-2032)
  21. 6.9.2 South America PECAM-1 Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PECAM-1 Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PECAM-1 Antibody Sales Value Share by Country, 2025 VS 2032
7 PECAM-1 Antibody Country-level Sales and Value Analysis
  1. 7.1 Global PECAM-1 Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PECAM-1 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PECAM-1 Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global PECAM-1 Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global PECAM-1 Antibody Sales by Country (2027-2032)
  6. 7.4 Global PECAM-1 Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global PECAM-1 Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global PECAM-1 Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PECAM-1 Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PECAM-1 Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PECAM-1 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher
  2. 8.1.1 Thermo Fisher Company Information
  3. 8.1.2 Thermo Fisher Business Overview
  4. 8.1.3 Thermo Fisher PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher PECAM-1 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Recent Developments
  7. 8.2 YO Proteins
  8. 8.2.1 YO Proteins Company Information
  9. 8.2.2 YO Proteins Business Overview
  10. 8.2.3 YO Proteins PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 YO Proteins PECAM-1 Antibody Product Portfolio
  12. 8.2.5 YO Proteins Recent Developments
  13. 8.3 US Biological
  14. 8.3.1 US Biological Company Information
  15. 8.3.2 US Biological Business Overview
  16. 8.3.3 US Biological PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 US Biological PECAM-1 Antibody Product Portfolio
  18. 8.3.5 US Biological Recent Developments
  19. 8.4 SICGEN
  20. 8.4.1 SICGEN Company Information
  21. 8.4.2 SICGEN Business Overview
  22. 8.4.3 SICGEN PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 SICGEN PECAM-1 Antibody Product Portfolio
  24. 8.4.5 SICGEN Recent Developments
  25. 8.5 Santa Cruz Biotechnology
  26. 8.5.1 Santa Cruz Biotechnology Company Information
  27. 8.5.2 Santa Cruz Biotechnology Business Overview
  28. 8.5.3 Santa Cruz Biotechnology PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Santa Cruz Biotechnology PECAM-1 Antibody Product Portfolio
  30. 8.5.5 Santa Cruz Biotechnology Recent Developments
  31. 8.6 Rockland Immunochemicals
  32. 8.6.1 Rockland Immunochemicals Company Information
  33. 8.6.2 Rockland Immunochemicals Business Overview
  34. 8.6.3 Rockland Immunochemicals PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Rockland Immunochemicals PECAM-1 Antibody Product Portfolio
  36. 8.6.5 Rockland Immunochemicals Recent Developments
  37. 8.7 R&D Systems
  38. 8.7.1 R&D Systems Company Information
  39. 8.7.2 R&D Systems Business Overview
  40. 8.7.3 R&D Systems PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 R&D Systems PECAM-1 Antibody Product Portfolio
  42. 8.7.5 R&D Systems Recent Developments
  43. 8.8 Proteintech Group
  44. 8.8.1 Proteintech Group Company Information
  45. 8.8.2 Proteintech Group Business Overview
  46. 8.8.3 Proteintech Group PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Proteintech Group PECAM-1 Antibody Product Portfolio
  48. 8.8.5 Proteintech Group Recent Developments
  49. 8.9 OriGene
  50. 8.9.1 OriGene Company Information
  51. 8.9.2 OriGene Business Overview
  52. 8.9.3 OriGene PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 OriGene PECAM-1 Antibody Product Portfolio
  54. 8.9.5 OriGene Recent Developments
  55. 8.10 Novus Biologicals
  56. 8.10.1 Novus Biologicals Company Information
  57. 8.10.2 Novus Biologicals Business Overview
  58. 8.10.3 Novus Biologicals PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novus Biologicals PECAM-1 Antibody Product Portfolio
  60. 8.10.5 Novus Biologicals Recent Developments
  61. 8.11 Miltenyi Biotec
  62. 8.11.1 Miltenyi Biotec Company Information
  63. 8.11.2 Miltenyi Biotec Business Overview
  64. 8.11.3 Miltenyi Biotec PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Miltenyi Biotec PECAM-1 Antibody Product Portfolio
  66. 8.11.5 Miltenyi Biotec Recent Developments
  67. 8.12 MilliporeSigma
  68. 8.12.1 MilliporeSigma Company Information
  69. 8.12.2 MilliporeSigma Business Overview
  70. 8.12.3 MilliporeSigma PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 MilliporeSigma PECAM-1 Antibody Product Portfolio
  72. 8.12.5 MilliporeSigma Recent Developments
  73. 8.13 LifeSpan Biosciences
  74. 8.13.1 LifeSpan Biosciences Company Information
  75. 8.13.2 LifeSpan Biosciences Business Overview
  76. 8.13.3 LifeSpan Biosciences PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 LifeSpan Biosciences PECAM-1 Antibody Product Portfolio
  78. 8.13.5 LifeSpan Biosciences Recent Developments
  79. 8.14 Enzo Life Sciences
  80. 8.14.1 Enzo Life Sciences Company Information
  81. 8.14.2 Enzo Life Sciences Business Overview
  82. 8.14.3 Enzo Life Sciences PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Enzo Life Sciences PECAM-1 Antibody Product Portfolio
  84. 8.14.5 Enzo Life Sciences Recent Developments
  85. 8.15 Dianova
  86. 8.15.1 Dianova Company Information
  87. 8.15.2 Dianova Business Overview
  88. 8.15.3 Dianova PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dianova PECAM-1 Antibody Product Portfolio
  90. 8.15.5 Dianova Recent Developments
  91. 8.16 Creative Biomart
  92. 8.16.1 Creative Biomart Company Information
  93. 8.16.2 Creative Biomart Business Overview
  94. 8.16.3 Creative Biomart PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Creative Biomart PECAM-1 Antibody Product Portfolio
  96. 8.16.5 Creative Biomart Recent Developments
  97. 8.17 Boster
  98. 8.17.1 Boster Company Information
  99. 8.17.2 Boster Business Overview
  100. 8.17.3 Boster PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Boster PECAM-1 Antibody Product Portfolio
  102. 8.17.5 Boster Recent Developments
  103. 8.18 Bon Opus Biosciences
  104. 8.18.1 Bon Opus Biosciences Company Information
  105. 8.18.2 Bon Opus Biosciences Business Overview
  106. 8.18.3 Bon Opus Biosciences PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bon Opus Biosciences PECAM-1 Antibody Product Portfolio
  108. 8.18.5 Bon Opus Biosciences Recent Developments
  109. 8.19 Bio-Rad
  110. 8.19.1 Bio-Rad Company Information
  111. 8.19.2 Bio-Rad Business Overview
  112. 8.19.3 Bio-Rad PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bio-Rad PECAM-1 Antibody Product Portfolio
  114. 8.19.5 Bio-Rad Recent Developments
  115. 8.20 BioLegend
  116. 8.20.1 BioLegend Company Information
  117. 8.20.2 BioLegend Business Overview
  118. 8.20.3 BioLegend PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 BioLegend PECAM-1 Antibody Product Portfolio
  120. 8.20.5 BioLegend Recent Developments
  121. 8.21 Abnova
  122. 8.21.1 Abnova Company Information
  123. 8.21.2 Abnova Business Overview
  124. 8.21.3 Abnova PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Abnova PECAM-1 Antibody Product Portfolio
  126. 8.21.5 Abnova Recent Developments
  127. 8.22 Abeomics
  128. 8.22.1 Abeomics Company Information
  129. 8.22.2 Abeomics Business Overview
  130. 8.22.3 Abeomics PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Abeomics PECAM-1 Antibody Product Portfolio
  132. 8.22.5 Abeomics Recent Developments
  133. 8.23 Abcam
  134. 8.23.1 Abcam Company Information
  135. 8.23.2 Abcam Business Overview
  136. 8.23.3 Abcam PECAM-1 Antibody Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Abcam PECAM-1 Antibody Product Portfolio
  138. 8.23.5 Abcam Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PECAM-1 Antibody Value Chain Analysis
  2. 9.1.1 PECAM-1 Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PECAM-1 Antibody Sales Mode & Process
  6. 9.2 PECAM-1 Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PECAM-1 Antibody Distributors
  9. 9.2.3 PECAM-1 Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst